Kangzhe Xie

Mr. Kangzhe Xie

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2025 in Bioscience Reports
Verified
Journal Article
Open access
KXKangzhe Xie
Kangzhe Xie
JHJordan Hunter
Jordan Hunter
ALAaron Lee
Aaron Lee
Gulfam AhmadGulfam Ahmad
Gulfam Ahmad
Paul WittingPaul Witting
Paul Witting
TOTamara Ortiz
Tamara Ortiz
Inflammatory bowel disease (IBD) is a gastrointestinal disorder characterised by elevated colonic neutrophil extracellular traps (NETs), which are associated with disease severity. Formation of NETs is primarily driven by peptidyl arginine deaminase IV (PAD4) and other enzymes including myeloperoxidase (MPO) and neutrophil elastase. The present study evaluated the effect of MPO and PAD4 inhibition in dextran sodium sulfate (DSS)-induced colitis. Experimental colitis was induced in male C57BL/6 mice by 2% w/v DSS in drinking water ad libitum. Treatment groups received daily oral administration of MPO inhibitor (AZD3241; 30 mg/kg) and/or intraperitoneal injection of PAD4 inhibitor (GSK484; 4 mg/kg) 4 times over 9 days. Inhibition of PAD4 significantly diminished NET density in the colonic mucosa of mice insulted with DSS, reaching levels similar to that detected in control mice. Both inhibitors offered limited improvement in disease-activity-index, a scoring system that considers the extent of weight loss, stool consistency and rectal bleeding. Histology showed that MPO and/or PAD4 inhibition did not recover DSS-induced colon histoarchitectural damage whilst Alcian blue staining demonstrated that PAD4 failed to reduce goblet cell loss. The selected dosage of PAD4 inhibition also yielded no effect on inflammatory markers and antioxidant protein levels. These data sets suggest that other mechanisms may be involved in the pathogenesis of IBD, and the appropriate dosage of GSK484 requires thorough investigation.

Verified
Journal Article
Open access
PDF file
TOTamara Ortiz
Tamara Ortiz
KXKangzhe Xie
Kangzhe Xie
AMAlbaraa Mojadadi
Albaraa Mojadadi
Paul WittingPaul Witting
Paul Witting
Innate and adaptive immune responses comprise a complex network of protein–protein and protein–cell interactions that regulates commensal flora and protects organisms from foreign pathogens and transformed (proliferating) host cells under physiological conditions such as pregnancy, growth and development as well as formulating a response pathological challenge

Verified
Journal Article
Open access
PDF file
AGAntony Gao
Antony Gao
KXKangzhe Xie
Kangzhe Xie
SGSameesh Gupta
Sameesh Gupta
Gulfam AhmadGulfam Ahmad
Gulfam Ahmad
Paul WittingPaul Witting
Paul Witting
Acute-phase serum amyloid A (SAA) can disrupt vascular homeostasis and is elevated in subjects with diabetes, cardiovascular disease, and rheumatoid arthritis. Cyclic nitroxides (e.g., Tempo) are a class of piperidines that inhibit oxidative stress and inflammation. This study examined whether 4-methoxy-Tempo (4-MetT) inhibits SAA-mediated vascular and renal dysfunction. Acetylcholine-mediated vascular relaxation and aortic guanosine-3′,5′-cyclic monophosphate (cGMP) levels both diminished in the presence of SAA. 4-MetT dose-dependently restored vascular function with corresponding increases in cGMP. Next, male ApoE-deficient mice were administered a vehicle (control, 100 µL PBS) or recombinant SAA (100 µL, 120 µg/mL) ± 4-MetT (at 15 mg/kg body weight via i.p. injection) with the nitroxide administered before (prophylaxis) or after (therapeutic) SAA. Kidney and hearts were harvested at 4 or 16 weeks post SAA administration. Renal inflammation increased 4 weeks after SAA treatment, as judged by the upregulation of IFN-γ and concomitant increases in iNOS, p38MAPK, and matrix metalloproteinase (MMP) activities and increased renal fibrosis (Picrosirius red staining) in the same kidneys. Aortic root lesions assessed at 16 weeks revealed that SAA enhanced lesion size (vs. control; p < 0.05), with plaque presenting with a diffuse fibrous cap (compared to the corresponding aortic root from control and 4-MetT groups). The extent of renal dysfunction and aortic lesion size was largely unchanged in 4-MetT-supplemented mice, although renal fibrosis diminished at 16 weeks, and aortic lesions presented with redistributed collagen networks. These outcomes indicate that SAA stimulates renal dysfunction through promoting the IFN-γ–iNOS–p38MAPK axis, manifesting as renal damage and enhanced atherosclerotic lesions, while supplementation with 4-MetT only affected some of these pathological changes.

16 February 2026 in Redox Report
Verified
Journal Article
Open access
ABAni T. Baker
Ani T. Baker
TOTamara Ortiz
Tamara Ortiz
KXKangzhe Xie
Kangzhe Xie
JHJordan Hunter
Jordan Hunter
IDIliya Dragutinovic
Iliya Dragutinovic
HHHugh Harris
Hugh Harris
Selenium nanoparticles (SeNPs) and selenoneine (SeN) are prospective nutritional supplements and therapeutic agents postulated to counteract Se deficiency and alleviate oxidative stress induced by various pathological conditions. X-ray fluorescence microscopy (XFM) and high energy resolution fluorescence detected X-ray absorption spectroscopy (HERFD-XAS) investigated Se distribution and speciation in mice fed supranutritional doses of SeNPs (10 mg Se/kg in feed) and SeN (5 mg Se/kg in feed). Mice fed control and SeNP diets showed equivalent Se distributions in the liver and testes, however, Se concentrations were elevated in the renal tubules of mice supplemented with SeNPs. Negligible differences in the composition of selenospecies were detected in tissues from mice fed SeNPs and control diets. Mice supplemented with SeN exhibited significant elevations in Se across all analysed tissues. Se Kα1 HERFD-XAS data revealed reduced SeN as the predominant selenospecies in tissues and blood from mice fed the SeN diet. Characterisation of the SeN-enriched feed showed that SeN was initially present in both the oxidised dimer and reduced monomer forms. These results support the hypothesised in vivo reduction of SeN and subsequent bioaccumulation in the blood and various tissues. The present findings highlight marked differences in the bioavailability and utilisation of these purported therapeutic selenocompounds.